Merck & Co., Inc. (NYSE:MRK – Get Free Report) was downgraded by stock analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.
Several other equities analysts also recently commented on MRK. Barclays increased their target price on Merck & Co., Inc. from $140.00 to $150.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. Daiwa Securities Group raised Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 price objective for the company in a research note on Wednesday, August 12th. Jefferies Financial Group downgraded Merck & Co., Inc. from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 19th. BMO Capital Markets raised their price objective on shares of Merck & Co., Inc. from $142.00 to $170.00 and gave the company an “outperform” rating in a report on Thursday, August 20th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the stock an “overweight” rating in a research report on Monday, July 13th. Seventeen analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat, Merck & Co., Inc. currently has a consensus rating of “Moderate Buy” and a consensus target price of $151.32.
Read Our Latest Analysis on Merck & Co., Inc.
Merck & Co., Inc. Stock Performance
Merck & Co., Inc. (NYSE:MRK – Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.13. The company had revenue of $16.61 billion for the quarter, compared to the consensus estimate of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.Merck & Co., Inc.’s revenue for the quarter was up 5.1% on a year-over-year basis. During the same quarter last year, the business posted $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, equities analysts expect that Merck & Co., Inc. will post 2.76 EPS for the current fiscal year.
Insider Activity at Merck & Co., Inc.
In other Merck & Co., Inc. news, EVP Jennifer Zachary sold 80,315 shares of the business’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total transaction of $10,718,839.90. Following the completion of the sale, the executive vice president directly owned 45,509 shares of the company’s stock, valued at approximately $6,073,631.14. The trade was a 63.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP David R. Maraldo sold 18,706 shares of the stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $128.72, for a total value of $2,407,836.32. Following the completion of the sale, the executive vice president directly owned 18,212 shares of the company’s stock, valued at approximately $2,344,248.64. This trade represents a 50.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 228,238 shares of company stock valued at $29,977,783 over the last quarter. 0.17% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Merck & Co., Inc.
Several institutional investors have recently bought and sold shares of the stock. Round Rock Advisors LLC grew its stake in Merck & Co., Inc. by 0.7% during the 2nd quarter. Round Rock Advisors LLC now owns 9,901 shares of the company’s stock worth $1,272,000 after buying an additional 66 shares during the last quarter. Cascade Financial Partners LLC boosted its holdings in shares of Merck & Co., Inc. by 0.5% in the second quarter. Cascade Financial Partners LLC now owns 14,746 shares of the company’s stock valued at $1,895,000 after acquiring an additional 80 shares during the period. Somerset Trust Co grew its position in shares of Merck & Co., Inc. by 0.9% during the second quarter. Somerset Trust Co now owns 8,701 shares of the company’s stock worth $1,118,000 after acquiring an additional 81 shares during the last quarter. Stonebridge Financial Group LLC increased its holdings in shares of Merck & Co., Inc. by 0.9% in the 2nd quarter. Stonebridge Financial Group LLC now owns 8,747 shares of the company’s stock valued at $1,124,000 after acquiring an additional 81 shares during the period. Finally, Stronghold Wealth Management L.L.C. increased its holdings in shares of Merck & Co., Inc. by 2.6% in the 2nd quarter. Stronghold Wealth Management L.L.C. now owns 3,237 shares of the company’s stock valued at $416,000 after acquiring an additional 82 shares during the period. Institutional investors own 76.07% of the company’s stock.
Trending Headlines about Merck & Co., Inc.
Here are the key news stories impacting Merck & Co., Inc. this week:
- Positive Sentiment: HSBC raised its price target for Merck (MRK) from $150 to $172 and maintained a “Buy” rating, implying substantial upside from the recent share price. Benzinga analyst update
- Positive Sentiment: Guggenheim also increased its Merck price target to $170, reinforcing the view that the company’s pipeline, newer medicines and potential cancer-drug combinations can support growth beyond Keytruda. Guggenheim increases Merck price target
- Positive Sentiment: Merck is expanding its development pipeline and commercial portfolio to reduce reliance on Keytruda ahead of its 2028 patent and exclusivity challenges. This provides a longer-term growth narrative, although execution and successful launches remain important. Merck pipeline and new drugs
- Neutral Sentiment: Merck’s stock attracted significant investor attention, but the coverage offers limited new fundamental information. Separately, broader pharmaceutical discussion highlighted manufacturing hurdles for personalized cancer vaccines and risks surrounding confidential industry information. Merck and cancer-vaccine risks
- Negative Sentiment: Investors remain concerned that Merck’s valuation looks demanding relative to its growth rate and to faster-growing peers such as Eli Lilly. Those concerns, combined with the future Keytruda revenue gap, likely contributed to the recent weakness despite higher analyst targets. Merck valuation versus Eli Lilly
Merck & Co., Inc. Company Profile
Merck & Co, Inc is a global healthcare company that develops, manufactures, and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets worldwide through its Human Health and Animal Health businesses.
Merck’s pharmaceutical portfolio includes oncology, infectious disease, cardiology, immunology, and other therapeutic areas. Its products include Keytruda, an immunotherapy used to treat various cancers; Gardasil, a vaccine that helps protect against human papillomavirus (HPV); and Januvia, a treatment for type 2 diabetes.
Featured Stories
- Five stocks we like better than Merck & Co., Inc.
- Why Bitcoin ETFs May Be Worth Another Look as Inflows Rebound
- 3 Small-Cap Biotechs With Binary Catalysts on the Calendar
- Planet Labs Has Fallen Back to Earth, But Wall Street Still Sees a Rebound
- As Homeowners’ Premiums Surge, This Insurer Is Posting Record Profits
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
